J. Kochan

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS‐1040, an Inhibitor of the Activated Form of Thrombin‐Activatable Fibrinolysis Inhibitor, in Healthy Subjects

O. Yin, F. Kobayashi, G. Atiee, 2019, Journal of clinical pharmacology.

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.

D. Parasrampuria, Ling He, K. Brown, 2015, Thrombosis research.

Safety and Pharmacokinetics of DS‐1040 Drug‐Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin

C. Rambaran, F. Pizzagalli, F. Kobayashi, 2020, Journal of clinical pharmacology.

A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects

O. Yin, G. Atiee, J. Zhou, 2017, Journal of thrombosis and haemostasis : JTH.

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

F. Meric-Bernstam, P. LoRusso, G. Schwartz, 2018 .

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

M. Andreeff, C. Dinardo, R. Olin, 2016 .

Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.

F. Depasse, Ling He, A. Vandell, 2017, Thrombosis research.